Plain-English translation of NCT05740956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is designed to target cancer cells that have specific genetic mutations related to DNA repair. The study will evaluate whether the medication is safe, well-tolerated, and effective in treating several types of advanced cancer, including ovarian, breast, pancreatic, prostate, and colorectal cancers.
Many cancers have mutations that make them vulnerable to this type of treatment, but patients need safe and effective options, especially when standard treatments haven't worked or aren't available. This medication aims to provide a new treatment path for people with these specific genetic mutations.
You likely qualify if…
You likely don't qualify if…
Participants will take the medication by mouth once daily as tablets. You will visit the study center regularly for check-ups, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study involves different phases and focuses on different cancer types, so the exact length and number of visits may vary, but you should expect ongoing monitoring as long as you remain on the treatment and benefit from it.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China